Solventum Corp
SOLV- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001964738
No open-market purchases or sales by Solventum Corp insiders were filed in the last 90 days; 891 institutions reported holding it in 13F filings for Q2 2026, worth $9.84B in total; Trian Fund Management is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 11:02 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 |
| Revenue | $8.32B | $8.25B |
| Gross profit | $4.45B | $4.59B |
| Research and development | $739.0M | $775.0M |
| Selling, general and administrative | $3.08B | $2.78B |
| Operating income | $2.18B | $1.04B |
| Income tax | $157.0M | $127.0M |
| Net income | $1.56B | $479.0M |
| EPS, basic | $8.94 | $2.77 |
| EPS, diluted | $8.88 | $2.76 |
| Weighted shares, basic | 174.1M | 173.2M |
| Weighted shares, diluted | 175.3M | 173.7M |
| Margins and growth | ||
| Gross margin | 53.5% | 55.6% |
| Operating margin | 26.2% | 12.6% |
| Net margin | 18.7% | 5.8% |
| Revenue growth, year over year | +0.9% | – |
| Net income growth, year over year | +224.8% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 |
| Cash and equivalents | $878.0M | $762.0M |
| Accounts receivable | $1.03B | $1.04B |
| Inventory | $1.07B | $965.0M |
| Total current assets | $3.86B | $3.25B |
| Property, plant and equipment | $1.33B | $1.62B |
| Goodwill | $5.70B | $6.38B |
| Intangible assets | $2.59B | $2.54B |
| Total assets | $14.3B | $14.5B |
| Accounts payable | $687.0M | $618.0M |
| Short-term debt | $0 | $200.0M |
| Total current liabilities | $3.14B | $2.70B |
| Long-term debt | $5.04B | $7.81B |
| Total liabilities | $9.24B | $11.5B |
| Shareholders' equity | $5.05B | $2.96B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 |
| Operating cash flow | $369.0M | $1.19B |
| Capital expenditures | $379.0M | $380.0M |
| Free cash flow | -$10.0M | $805.0M |
| Depreciation and amortization | $489.0M | $555.0M |
| Stock-based compensation | $161.0M | $112.0M |
| Investing cash flow | $2.80B | -$380.0M |
| Financing cash flow | -$3.06B | -$240.0M |
| Net change in cash | $116.0M | $568.0M |
| Ratio | ||
| Stock-based compensation, % of revenue | 1.9% | 1.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 169.7M | −2.1% | SEC |
| Jul 31, 2026 | 170.2M | −1.8% | SEC |
| Apr 30, 2026 | 173.2M | +0.1% | SEC |
| Feb 18, 2026 | 173.5M | +0.3% | SEC |
| Oct 31, 2025 | 173.4M | +0.4% | SEC |
| Jul 31, 2025 | 173.4M | +0.4% | SEC |
| Apr 30, 2025 | 173.0M | +0.2% | SEC |
| Feb 21, 2025 | 173.0M | +0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.